Alzheimer’s Disease is the most common cause of dementia, constituting 60% to 70% of all cases, and the risk with the disease doubles every 5 years after age 65. Incidence of the disease is increasing, and the resulting attention given to Alzheimer's Disease has encouraged development of new treatments. There is an opportunity for pharmaceutical companies to compete in this market, as Kalorama analyst Melissa Elder outlines in this study.

This report includes incidence of Alzheimer’s disease worldwide with information for specific geographical regions; world demographics; life expectancy by country, and other general issues affecting the market.

Information is presented as a worldwide overview, with special emphasis on the U.S., Japan, Germany, and other key markets.

A market summary includes market analysis by products on the market and in development, in addition to a a regional market analysis, including:

• US
• Europe
• Japan
• Rest of World

as well as a competitive analysis of leading providers. Additionally key company profiles are included, with profiles of the following companies competing in this therapeutic area:

• Eisai Co., Ltd.
• Forest Laboratories
• H. Lundbeck A/S
• Johnson & Johnson
• Merz Pharma GmbH
• Novartis AG
• Pfizer, Inc.

Markets are broken out by drug type:

• Cholinesterase inhibitors
• NMDA antagonists

as well as by product.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information.

For the purpose of this study, Kalorama Information conducted interviews with more than 50 key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Additional interviews were completed with relevant company representatives including marketing directors, division managers, and product representatives.

All market data pertains to the world market at the manufacturers’ level. The base year for data was 2007. Historical data was provided for the years 2005 and 2006, with forecast data provided for 2008 through 2012. Compound annual growth rates (CAGRs) are provided for the 2005-2007 and 2008-2012 periods for each region and/or segment covered. Competitive analysis is provided for the year 2007.

Related Reports:

Smoking Cessation: World Markets
Nov 1, 2008 - KLI1646594 - $3,500.00

Glucose Testing Markets
Nov 1, 2008 - KLI1911068 - $1,995.00

Blood: The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products
Nov 1, 2008 - KLI1816262 - $3,995.00

Pharmaceutical Markets in the Middle East (Opportunities, Key Players, Trends in Egypt, Jordan, Israel, Saudi Arabia and UAE)
Nov 1, 2008 - KLI1646593 - $3,300.00

Outsourcing in Drug Development: The Contract CRO Market, 3rd Edition
Oct 1, 2008 - KLI1646604 - $3,500.00

Worldwide In Vitro Diagnostics Market Research Bundle (Worldwide Market for In Vitro Diagnostic Tests, SNP Genotyping Markets, Companion Diagnostics, Testing Services Markets)
Oct 1, 2008 - KLI1927625 - $7,995.00

HIV: Markets for Diagnostics and Therapeutics
Oct 1, 2008 - KLI1646600 - $3,500.00

Kalorama Medical Device Market Research Bundle: Infusion Pumps, Minimally Invasive Devices, Syringes, Hip and Knee Implants, Respiratory Equipment, Asian Device Markets, OEM Contract Manufacturing, Reusable Equipment, Catheters)
Oct 1, 2008 - KLI1927457 - $9,995.00

Minimally Invasive Surgical Devices, World Market
Sep 1, 2008 - KLI1614100 - $3,500.00

Facial Rejuvenation Markets Worldwide
Aug 1, 2008 - KLI1190879 - $3,500.00